08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

CDX-301: Interim Phase II data

Interim data from 3 sibling-matched donors for allogeneic hematopoietic stem cell transplant (HSCT) recipients with hematologic malignancies in an open-label, U.S. Phase II trial showed that 75 ug/kg/day subcutaneous CDX-301 given to the donor for...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

CDX-301: Pilot trial started

Celldex began an open-label, U.S. pilot trial to evaluate CDX-301 for 5 or 7 days alone and in combination with Mozobil plerixafor in up to 18 human leukocyte antigen (HLA)-matched donor/recipient sibling pairs....
08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

CDX-301: Phase I data

Data from 18 healthy volunteers in an open-label, dose-escalation, U.S. Phase I trial showed that once-daily subcutaneous CDX-301 for 5-10 days was well tolerated up to 25 µg/kg. There was 1 dose-limiting toxicity (DLT) of...
08:00 , Jan 23, 2012 |  BC Week In Review  |  Clinical News

CDX-301: Phase I started

Celldex began an open-label, dose-escalation, U.S. Phase I trial to evaluate 1-75 mg/kg IV or subcutaneous CDX-301 for 5-10 days in about 30 healthy volunteers. Celldex has exclusive rights to develop and commercialize CDX-301 from...